TBPH - テラバンス・バイオファ―マ （Theravance Biopharma Inc.） テラバンス・バイオファ―マTBPHのチャート
TBPHの企業情報
| symbol | TBPH |
|---|---|
| 会社名 | Theravance Biopharma Inc. （テラバンス・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 セラバンス・バイオファーマ(Theravance Biopharma Inc.)はバイオ医薬品会社である。同社は重病患者のための医薬品の製造に従事する。同社はヒト治療法の発見（研究）・開発・商業化の分野で事業を行う。同社の内部で発見された製品候補のパイプラインには、主に急性期ケア環境で重篤な状態で治療されている患者の満たされていないニーズに対応するための医薬品が含まれる。製品VIBATIV（テラバンシン）は、特定の治療が困難な感染症向けの一日一回の二重機構の抗生物質であり、米国および欧州で承認される。レベフェナシン（TD-4208）は、長期作用性ムスカリンアンタゴニスト（LAMA）であり、慢性閉塞性肺疾患のための噴霧治療として開発される。ネプリライシン（NEP）阻害剤プログラムは、一連の心血管疾患および腎疾患の治療のための選択的NEP阻害剤を開発するように設計されている。 テラバンス・バイオファ―マは細菌感染症と呼吸器系疾患に焦点を置く米国のバイオ医薬品会社。重度の感染症の治療用に1日1回投与の抗菌薬注射剤「VIBATIVTM(一般名:テラバンシン)」を商品化。また、製品パイプラインに慢性閉塞性肺疾患の治療用のTD-4208とオピオイド誘発性便秘薬Axelopran(TD-1211)を含む。 Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology. |
| 本社所在地 | P.O. Box 309 Ugland House South Church Street George Town Grand Cayman KY1-1104 CYM |
| 代表者氏名 | Rick E. Winningham リックE.ウィニングハム |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 345-650808-6000 |
| 設立年月日 | 41456 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 340人 |
| url | www.theravance.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tbph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -246.19500 |
| 終値（lastsale） | 32.555 |
| 時価総額（marketcap） | 1793914854.485 |
| 時価総額 | 時価総額（百万ドル） 1644.307 |
| 売上高 | 売上高（百万ドル） 40.58500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1515.686 |
| 当期純利益 | 当期純利益（百万ドル） -259.70400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Theravance Biopharma Inc revenues increased from $6.6M to $31.8M. Net loss decreased 20% to $105.9M. Revenues reflect Revenue from collaborative arrangements increase from $72K to $22.8M Product sales increase of 39% to $9M. Lower net loss reflects Research and development - bal decrease of 31% to $50.5M (expense) Interest and other income increase of 41% to $3.5M (income). |
TBPHのテクニカル分析
TBPHのニュース
Top Healthcare Stocks for April 2023 2023/03/30 21:22:28 Investopedia
Top healthcare stocks include Theravance Biopharma for best value, ShockWave Medical for fastest growth, and Ardelyx for most momentum.
Top Healthcare Stocks for March 2023 2023/03/08 19:50:22 Investopedia
Top healthcare stocks include Theravance Biopharma for best value, Signify Health for fastest growth, and TransMedics Group for most momentum.
Theravance Biopharma, Inc. 2022 Q4 - Results - Earnings Call Presentation 2023/03/08 19:09:19 Seeking Alpha
The following slide deck was published by Theravance Biopharma, Inc.
Theravance Biopharma Inc. (TBPH) Q4 2022 Earnings Call Transcript 2023/02/28 02:25:20 Seeking Alpha
Theravance Biopharma Inc. (NASDAQ:NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsRick Winningham - Chairman and Chief Executive OfficerRhonda…
Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17% 2023/02/27 21:24:29 Seeking Alpha
Theravance Biopharma press release (TBPH): Q4 GAAP EPS of -$0.15 beats by $0.02.Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M.Discontinuing investments in research, reducing…
Theravance Biopharma Inc. (TBPH) Q4 2022 Earnings Call Transcript 2023/02/28 02:25:20 Seeking Alpha
Theravance Biopharma Inc. (NASDAQ:NASDAQ:TBPH) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsRick Winningham - Chairman and Chief Executive OfficerRhonda…
Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17% 2023/02/27 21:24:29 Seeking Alpha
Theravance Biopharma press release (TBPH): Q4 GAAP EPS of -$0.15 beats by $0.02.Revenue of $14.6M (-2.3% Y/Y) misses by $1.13M.Discontinuing investments in research, reducing…
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update 2023/02/27 21:05:00 PR Newswire
Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments in research, reducing headcount by approximately 17% Reports highest quarter of YUPELRI (revefenacin) net sales and profitability…
Earnings Preview: Theravance Biopharma 2023/02/24 20:02:25 Benzinga
Theravance Biopharma (NASDAQ: TBPH ) is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here''s what investors need to know before the announcement. Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.17. Theravance Biopharma bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 2023/02/21 11:00:00 PR Newswire
DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023. An accompanying conference call and simultaneous webcast will…
Theravance Biopharma to Participate in an Upcoming Investor Conference 2023/02/09 11:00:00 PR Newswire
DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 8:00 am ET (5:00 am PT/1:00 pm GMT). Webcast of the event may be accessed by visiting…
Investing in Theravance Biopharma Inc. (TBPH) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/16 18:24:00 US Post News
A share of Theravance Biopharma Inc. (NASDAQ:TBPH) closed at $11.30 per share on Friday, up from $11.02 day before. While Theravance Biopharma Inc. has overperformed by 2.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 18.82%, with highs and lows ranging from $11.83 […]
Investing in Theravance Biopharma Inc. (TBPH) might be a great opportunity, but the stock is a bit overvalued 2022/12/05 14:40:00 US Post News
In Friday’s session, Theravance Biopharma Inc. (NASDAQ:TBPH) marked $11.02 per share, up from $10.80 in the previous session. While Theravance Biopharma Inc. has overperformed by 2.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 34.55%, with highs and lows ranging from $13.17 to […]
Do investors need to be concerned about Theravance Biopharma Inc. (TBPH)? 2022/11/25 13:32:00 US Post News
In Wednesday’s session, Theravance Biopharma Inc. (NASDAQ:TBPH) marked $10.27 per share, down from $10.61 in the previous session. While Theravance Biopharma Inc. has underperformed by -3.20%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TBPH rose by 21.54%, with highs and lows ranging from $13.17 to […]
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer | MarketScreener 2022/11/18 11:01:04 MarketScreener
DUBLIN, Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. today announced the preliminary results of its Dutch auction tender offer to purchase up to $95 million of its ordinary shares,… | November 18, 2022